Paloma Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-237,400
| Closed | -$6.87M | – | 874 |
|
|
2024
Q3 | $6.87M | Sell |
237,400
-2,600
| -1% | -$75.8K | 0.19% | 115 |
|
|
2024
Q2 | $6.72M | Buy |
+240,000
| New | +$6.61M | 0.19% | 71 |
|
|
2023
Q4 | – | Sell |
-313,700
| Closed | -$10.4M | – | 896 |
|
|
2023
Q3 | $10.4M | Buy |
313,700
+120,400
| +62% | +$4.26M | 0.36% | 42 |
|
|
2023
Q2 | $7.09M | Sell |
193,300
-190,900
| -50% | -$7.43M | 0.25% | 64 |
|
|
2023
Q1 | $15.7M | Buy |
384,200
+375,700
| +4,420% | +$16.2M | 0.55% | 20 |
|
|
2022
Q4 | $436K | Sell |
8,500
-118,600
| -93% | -$5.69M | 0.02% | 551 |
|
|
2022
Q3 | $5.56M | Buy |
+127,100
| New | +$6.18M | 0.25% | 53 |
|
|
2022
Q2 | – | Sell |
-96,700
| Closed | -$5.01M | – | 1598 |
|
|
2022
Q1 | $5.01M | Buy |
+96,700
| New | +$5.02M | 0.15% | 89 |
|
|
2021
Q2 | – | Sell |
-255,200
| Closed | -$9.25M | – | 2157 |
|
|
2021
Q1 | $9.25M | Buy |
+255,200
| New | +$9.06M | 0.2% | 82 |
|
|
2020
Q1 | – | Sell |
-97,179
| Closed | -$3.61M | – | 1868 |
|
|
2019
Q4 | $3.61M | Sell |
97,179
-137,020
| -59% | -$4.88M | 0.05% | 361 |
|
|
2019
Q3 | $7.98M | Buy |
+234,199
| New | +$8.52M | 0.17% | 96 |
|
|
2018
Q4 | – | Sell |
-305,765
| Closed | -$12.8M | – | 1665 |
|
|
2018
Q3 | $12.8M | Buy |
305,765
+159,786
| +109% | +$6.15M | 0.23% | 59 |
|
|
2018
Q2 | $5.03M | Buy |
145,979
+90,644
| +164% | +$3.1M | 0.09% | 178 |
|
|
2018
Q1 | $1.86M | Sell |
55,335
-111,408
| -67% | -$3.83M | 0.03% | 620 |
|
|
2017
Q4 | $5.73M | Buy |
166,743
+92,963
| +126% | +$3.17M | 0.08% | 243 |
|
|
2017
Q3 | $2.5M | Sell |
73,780
-26,350
| -26% | -$847K | 0.03% | 606 |
|
|
2017
Q2 | $3.19M | Sell |
100,130
-114,148
| -53% | -$3.6M | 0.04% | 491 |
|
|
2017
Q1 | $6.96M | Buy |
214,278
+100,973
| +89% | +$3.18M | 0.08% | 199 |
|
|
2016
Q4 | $3.49M | Sell |
113,305
-76,415
| -40% | -$2.33M | 0.03% | 400 |
|
|
2016
Q3 | $6.1M | Hold |
189,720
| – | – | 0.08% | 155 |
|
|
2016
Q2 | $6.34M | Sell |
189,720
-63,240
| -25% | -$2.02M | 0.07% | 191 |
|
|
2016
Q1 | $7.11M | Buy |
252,960
+147,560
| +140% | +$4.21M | 0.12% | 113 |
|
|
2015
Q4 | $3.23M | Buy |
105,400
+26,350
| +33% | +$829K | 0.09% | 206 |
|
|
2015
Q3 | $2.36M | Sell |
79,050
-487,686
| -86% | -$15.6M | 0.05% | 293 |
|
|
2015
Q2 | $18M | Buy |
+566,736
| New | +$18.5M | 0.35% | 60 |
|
Other funds holding PFE
Paloma Partners's PFE Position: Q4 2024 in Review
Paloma Partners sold out of Pfizer (PFE) in Q4 2024, closing a stake of 27,741 shares — an estimated $803K sold.
Paloma Partners first reported a position in PFE in Q2 2013 and held it in 35 quarters. The position peaked at $53.9M in Q1 2019. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.
- Paloma Partners reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
- Paloma Partners sold 27,741 Pfizer shares in Q4 2024, an estimated $803K.
- Paloma Partners first reported a position in Pfizer in Q2 2013 and held it in 35 quarters.
- Paloma Partners's Pfizer position peaked at $53.9M in Q1 2019.
- 2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.
Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.